{
    "ticker": "ASRT",
    "name": "Assertio Holdings, Inc.",
    "description": "Assertio Holdings, Inc. is a specialty pharmaceutical company dedicated to providing innovative and effective therapeutic solutions to patients. Founded in 1997, the company has evolved through strategic acquisitions and a focus on enhancing the quality of life for patients with rare and complex conditions. Assertio\u2019s product portfolio includes prescription medications that address various medical needs, particularly in the areas of pain management, neurology, and orphan diseases. The company's commitment to research and development is paramount, as it continuously seeks to improve existing treatments and develop new therapies that can significantly impact patient outcomes. Assertio aims to bring forth value-based solutions while navigating the complex healthcare landscape, ensuring that patients have access to necessary medications. With a robust pipeline of products and a strategic focus on leveraging partnerships, Assertio is poised for growth in the dynamic pharmaceutical industry. The company recognizes the importance of patient-centric approaches and strives to collaborate with healthcare professionals to better serve the medical community.",
    "industry": [
        "Pharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Lake Forest, Illinois, USA",
    "founded": "1997",
    "website": "https://www.assertiopharma.com",
    "ceo": "Danielle P. DeLuca",
    "social_media": {
        "twitter": "https://twitter.com/AssertioPharma",
        "linkedin": "https://www.linkedin.com/company/assertio-holdings/"
    },
    "investor_relations": "https://ir.assertiopharma.com",
    "key_executives": [
        {
            "name": "Danielle P. DeLuca",
            "position": "CEO"
        },
        {
            "name": "David D. Kahn",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pain Management",
            "products": [
                "Nucynta",
                "Nucynta ER"
            ]
        },
        {
            "category": "Neurology",
            "products": [
                "Gralise",
                "Zipsor"
            ]
        }
    ],
    "seo": {
        "meta_title": "Assertio Holdings, Inc. | Specialty Pharmaceuticals for Patient Care",
        "meta_description": "Explore Assertio Holdings, a specialty pharmaceutical company focused on innovative therapeutic solutions for patients. Learn about our commitment to improving patient outcomes.",
        "keywords": [
            "Assertio",
            "Pharmaceuticals",
            "Pain Management",
            "Neurology",
            "Healthcare"
        ]
    },
    "faq": [
        {
            "question": "What does Assertio specialize in?",
            "answer": "Assertio specializes in specialty pharmaceuticals, particularly in pain management and neurology."
        },
        {
            "question": "Who is the CEO of Assertio?",
            "answer": "Danielle P. DeLuca is the CEO of Assertio Holdings, Inc."
        },
        {
            "question": "Where is Assertio headquartered?",
            "answer": "Assertio is headquartered in Lake Forest, Illinois, USA."
        },
        {
            "question": "What are some of Assertio's main products?",
            "answer": "Some of Assertio's main products include Nucynta, Nucynta ER, Gralise, and Zipsor."
        },
        {
            "question": "When was Assertio founded?",
            "answer": "Assertio was founded in 1997."
        }
    ],
    "competitors": [
        "PTGX",
        "HRTX",
        "HCRN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "BMY"
    ]
}